USPTO serial 98338186
SYNERGICE
Reviewed by CopyMark Law Group
Status 819
- Filing date
- Status date
- Registration date
- —
- Examiner
- KIRCHGASSER, ROSS LEONARD
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SYNERGICE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Zach Gordon
Zach Gordon TAFT STETTINIUS & HOLLISTER1 INDIANA SQUARE, SUITE 3500INDIANAPOLIS, IN 46204United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations for treatment of Musculo skeletal pain; pharmaceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of Psychiatric disorders; pharmaceutical preparations for treatment of human immunodeficiency virus (HIV); pharmaceutical preparations for treatment Gastro Intestinal illnesses and disorders; pharmaceutical preparations for treatment of allergies; pharmaceutical preparations for treatment of viral illnesses; pharmaceutical preparations for treatment of bacterial illnesses; pharmaceutical preparations for diabetes management; pharmaceutical preparations for treatment of gout; pharmaceutical preparations for treatment of fungal infections; pharmaceutical preparations for treatment of attention deficit disorder; pharmaceutical preparations for treatment of immune disorders; pharmaceutical preparations for treatment of neurological disorders and neurological illness; pharmaceutical preparations for treatment of cardiovascular illnesses; pharmaceutical preparations for treatment of urological issues; pharmaceutical preparations for treatment of sleep disorders; pharmaceutical preparations for treatment of sexual disorders; pharmaceutical preparations for bronchodilation; pharmaceutical preparations for treatment of thyroid disorders; pharmaceutical preparations for treatment of hormonal disorders; Tablet preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; gelatin capsule preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; powder preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; syrup preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; cream preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; oral solution preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes | ACTIVE | Jun 24, 2026 |
| 035 | Business to business services in the nature of generating business leads, business development, providing business information, acting as single point of contact between clients and vendors for providing product and pricing information and facilitating commercial transactions, all of the forgoing in the field of generic pharmaceuticals | ACTIVE | Jun 24, 2026 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 3, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 3, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 2, 2026 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Nov 2, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 2, 2026 | ALIE | ASSIGNED TO LIE | — |
| Oct 27, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 28, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 28, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 28, 2026 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jun 24, 2026 | IUAF | USE AMENDMENT FILED | — |
| Jun 24, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| May 14, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 4, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 4, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 4, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 8, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 8, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 8, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 8, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 18, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 24, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 24, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 18, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 3, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 3, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 3, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 3, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 3, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 30, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 30, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 2, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 2, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 2, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 6, 2024 | NWAP | NEW APPLICATION ENTERED | — |